Novartis AG to Expand Portfolio with Regulus Therapeutics Acquisition

In a landmark deal that could reshape the biopharmaceutical landscape, Novartis AG has announced its agreement to acquire Regulus Therapeutics Inc. for up to $1.7 billion. This strategic move underscores Novartis' commitment to innovation and addressing unmet medical needs.

Deal Structure and Future Prospects

The acquisition includes an initial payment of $7.00 per share, totaling $0.8 billion, with an additional $7.00 per share contingent upon regulatory approval of farabursen, Regulus' lead product candidate. This contingent value right (CVR) highlights the potential of farabursen to treat ADPKD, a condition with limited treatment options.

Leadership and Vision

"This partnership with Novartis represents a pivotal moment for Regulus and the patients we serve. Novartis' global reach and expertise will be instrumental in bringing farabursen to those in need," said Jay Hagan, CEO of Regulus Therapeutics.

The transaction, pending regulatory approval and customary closing conditions, is anticipated to finalize in the latter half of 2025.